Sunshine Biopharma, Inc. SBFM
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.74% | -2.05% | 4.10% | 13.24% | 19.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.74% | -2.05% | 4.10% | 13.24% | 19.22% |
| Cost of Revenue | 1.68% | -5.56% | -0.64% | 9.60% | 14.22% |
| Gross Profit | -11.58% | 5.98% | 14.86% | 21.44% | 30.68% |
| SG&A Expenses | -8.61% | -0.85% | 2.96% | 22.07% | 39.46% |
| Depreciation & Amortization | 30.79% | 40.05% | 48.55% | 48.88% | 54.42% |
| Other Operating Expenses | 32.56% | 16.02% | 21.27% | 27.21% | 10.57% |
| Total Operating Expenses | -2.94% | -4.46% | 0.36% | 11.38% | 19.13% |
| Operating Income | 4.31% | 19.79% | 22.28% | 1.10% | -18.47% |
| Income Before Tax | 14.03% | -12.21% | -10.89% | -58.28% | -72.99% |
| Income Tax Expenses | 266.36% | 120.78% | 109.20% | -551.40% | -171.50% |
| Earnings from Continuing Operations | 7.52% | -20.07% | -16.38% | -41.81% | -71.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.52% | -20.07% | -16.38% | -41.81% | -71.39% |
| EBIT | 4.31% | 19.79% | 22.28% | 1.10% | -18.47% |
| EBITDA | 6.13% | 22.48% | 25.14% | 3.24% | -17.06% |
| EPS Basic | 63.89% | 70.76% | 75.38% | 59.03% | 30.60% |
| Normalized Basic EPS | 68.00% | 61.23% | 71.47% | 33.67% | -26.78% |
| EPS Diluted | 63.89% | 70.76% | 75.38% | 59.03% | 30.60% |
| Normalized Diluted EPS | 68.00% | 61.23% | 71.47% | 33.67% | -26.78% |
| Average Basic Shares Outstanding | 163.40% | 207.27% | 309.06% | 628.44% | 1,556.47% |
| Average Diluted Shares Outstanding | 163.40% | 178.15% | 253.29% | 445.33% | 728.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |